Mechanism and therapeutic strategy of coronary involvement of Kawasaki disease: dynamics of MMP and TIMP1 in isolated cells.
| Project/Area Number |
24591555
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Oita University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 川崎病 / MMP9 / TIMP1 / 顆粒球 / 血小板 |
|---|
| Outline of Final Research Achievements |
MMP9 and TIMP1, which have been reported to be associate with coronary involvement of Kawasaki disease, are distributed in the granulocytes and platelets, respectively. In this study we evaluated drug responsiveness of granulocyte-derived MMP9 and platelet-derived TIMP1.
Whole blood by patients with Kawasaki disease and healthy adult were collected, and then, their granulocytes and platelets were co-cultured with gamma-globulin, methylprednisolone and ulinastatin.
Only granulocyte-derived MMP9 decreased during co-cultured with gamma-globulin. Other medicines could not affect granulosyte-derived MMP9 and platelet-derived TIMP1. Gamma-globulin is effective in suppression of granulocyte-derived MMP9.
|
Report
(4 results)
Research Products
(10 results)
